Home Biosimilar Antibodies Others Others Ponsegromab (Anti-GDF15 / MIC-1)
For research use only. Not for use in humans.

Ponsegromab (Anti-GDF15 / MIC-1)

Synonyms: PF 06946860

Ponsegromab (Anti-GDF15 / MIC-1) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. MW: 145.5 KD.

Ponsegromab (Anti-GDF15 / MIC-1)

Quality Control

Batch: Purity: 99% Protein concentration: 10.518mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Ponsegromab (Anti-GDF15 / MIC-1) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. MW: 145.5 KD.

Product Details

CAS No. 2368950-15-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07663630 NOT_YET_RECRUITING Drug: ponsegromab|Drug: placebo Non-small Cell Lung Cancer (NSCLC); Cachexia Pfizer 2026-07-22 PHASE1
NCT06989437 RECRUITING Drug: ponsegromab|Drug: placebo Cachexia; Metastatic Pancreatic Ductal Adenocarcinoma Pfizer 2025-10-03 PHASE2; PHASE3
NCT06059547 COMPLETED Drug: Nivolumab|Drug: Visugromab (CTL-002)|Drug: Placebo Bladder Cancer; Adult Solid Tumor CatalYm GmbH 2023-09-06 PHASE2
NCT05492500 TERMINATED Drug: Main cohort (Cohort A): Ponsegromab low dose|Drug: Mai Heart Failure Pfizer 2022-09-26 PHASE2
NCT05546476 COMPLETED Drug: ponsegromab|Drug: Placebo for ponsegromab Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Loss of Appetite; Fatigue; Cachexia Pfizer 2022-11-21 PHASE2
NCT05685264 COMPLETED Drug: Ponsegromab|Drug: Ponsegromab Healthy Pfizer 2023-01-18 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-06-23)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.